Trial Profile
A Open-label, Randomized, Single-dose, 3-way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 2 Different Formulations of Orvepitant and the Effect of Food in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Orvepitant (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Food-rel-BA
- Sponsors GSK
- 18 Feb 2009 New trial record